hengrui glp-1 China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes Dealmakers push for next-generation obesity
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8




















:max_bytes(150000):strip_icc()/Health-GettyImages-2242656837-7ba7eeb1b08d43c681f154b32e6dc07c.jpg)



